The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle cell disease.
Average Price Target $88
Average recommendation BUY
Global Blood Therapeutics , Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)